- Markets
- Healthcare
- AAREYDRUGS
AAREYDRUGS
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Aarey Drugs And Pharmaceuticals To Issue 5 Million Warrants
Dec 4 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO ISSUE 5 MILLION WARRANTS
Source text: [ID:]
Further company coverage: ADPH.NS
(([email protected];))
Dec 4 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO ISSUE 5 MILLION WARRANTS
Source text: [ID:]
Further company coverage: ADPH.NS
(([email protected];))
Aarey Drugs And Pharmaceuticals To Consider Issue Of Shares
Nov 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUE OF SHARES
Source text: ID:nBSEbn4KYR
Further company coverage: ADPH.NS
(([email protected];;))
Nov 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUE OF SHARES
Source text: ID:nBSEbn4KYR
Further company coverage: ADPH.NS
(([email protected];;))
Aarey Drugs And Pharmaceuticals To Consider Proposal For Issuance Of Equity Shares
Nov 26 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS - TO CONSIDER A PROPOSAL FOR ISSUANCE OF EQUITY SHARES
Further company coverage: ADPH.NS
(([email protected];))
Nov 26 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS - TO CONSIDER A PROPOSAL FOR ISSUANCE OF EQUITY SHARES
Further company coverage: ADPH.NS
(([email protected];))
Aarey Drugs And Pharmaceuticals To Consider Issuance Of Shares
Aug 7 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO CONSIDER ISSUANCE OF SHARES VIA PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE1SNkdV
Further company coverage: ADPH.NS
(([email protected];))
Aug 7 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO CONSIDER ISSUANCE OF SHARES VIA PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE1SNkdV
Further company coverage: ADPH.NS
(([email protected];))
Aarey Drugs And Pharmaceuticals Withheld Consideration for Expansion, Raising Funds From Bank, to be finalised in forthcoming meeting
June 21 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER AND APPROVE EXPANSION, RAISING FUNDS FROM BANK
DECISION IS WITHHELD AND WILL BE FINALIZED IN FORTHCOMING BOARD MEETING
Source text for Eikon: ID:nNSEb16vHy
Further company coverage: ADPH.NS
(([email protected];))
June 21 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER AND APPROVE EXPANSION, RAISING FUNDS FROM BANK
DECISION IS WITHHELD AND WILL BE FINALIZED IN FORTHCOMING BOARD MEETING
Source text for Eikon: ID:nNSEb16vHy
Further company coverage: ADPH.NS
(([email protected];))
Aarey Drugs And Pharmaceuticals To Consider Issuance Of Shares By Preferential Allotment
June 16 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUANCE OF SHARES BY PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE934WG0
Further company coverage: ADPH.NS
(([email protected];;))
June 16 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUANCE OF SHARES BY PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE934WG0
Further company coverage: ADPH.NS
(([email protected];;))
India's Aarey Drugs And Pharmaceuticals Reports March-Quarter Profit Versus Loss
May 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
MARCH-QUARTER PROFIT 3.6 MILLION RUPEES VERSUS LOSS 7.6 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.2 BILLION RUPEES
Source text for Eikon: ID:nBSE1cnvHC
Further company coverage: ADPH.NS
(([email protected];))
May 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
MARCH-QUARTER PROFIT 3.6 MILLION RUPEES VERSUS LOSS 7.6 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.2 BILLION RUPEES
Source text for Eikon: ID:nBSE1cnvHC
Further company coverage: ADPH.NS
(([email protected];))
Events:
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Aarey Drugs & Pharma do?
Aarey Drugs & Pharmaceuticals Ltd. specializes in manufacturing drugs and intermediates like metronidazole and nitro imidazole. Their product focus areas include Allergy, Dermatology, and Infectious Diseases.
Who are the competitors of Aarey Drugs & Pharma?
Aarey Drugs & Pharma major competitors are Auro Laboratories, Vaishali Pharma, BDH Inds, Amwill Health Care, Tyche Inds, Bal Pharma, IndoAmerican Advance. Market Cap of Aarey Drugs & Pharma is ₹165 Crs. While the median market cap of its peers are ₹162 Crs.
Is Aarey Drugs & Pharma financially stable compared to its competitors?
Aarey Drugs & Pharma seems to be less financially stable compared to its competitors. Altman Z score of Aarey Drugs & Pharma is 2.76 and is ranked 5 out of its 8 competitors.
Does Aarey Drugs & Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aarey Drugs & Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Aarey Drugs & Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Short Term Loans & Advances
How strong is Aarey Drugs & Pharma balance sheet?
Balance sheet of Aarey Drugs & Pharma is moderately strong.
Is the profitablity of Aarey Drugs & Pharma improving?
Yes, profit is increasing. The profit of Aarey Drugs & Pharma is ₹5.7 Crs for TTM, ₹4.68 Crs for Mar 2024 and ₹3.77 Crs for Mar 2023.
Is the debt of Aarey Drugs & Pharma increasing or decreasing?
Yes, The debt of Aarey Drugs & Pharma is increasing. Latest debt of Aarey Drugs & Pharma is ₹37.16 Crs as of Sep-24. This is greater than Mar-24 when it was ₹29.66 Crs.
Is Aarey Drugs & Pharma stock expensive?
Yes, Aarey Drugs & Pharma is expensive. Latest PE of Aarey Drugs & Pharma is 28.89, while 3 year average PE is 22.43. Also latest EV/EBITDA of Aarey Drugs & Pharma is 35.69 while 3yr average is 28.27.
Has the share price of Aarey Drugs & Pharma grown faster than its competition?
Aarey Drugs & Pharma has given lower returns compared to its competitors. Aarey Drugs & Pharma has grown at ~-0.82% over the last 7yrs while peers have grown at a median rate of 10.0%
Is the promoter bullish about Aarey Drugs & Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Aarey Drugs & Pharma is 44.8% and last quarter promoter holding is 44.8%.
Are mutual funds buying/selling Aarey Drugs & Pharma?
There is Insufficient data to gauge this.